Designing biomaterials for the treatment of autoimmune diseases
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Advancements in Transdermal Drug Delivery · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Autoimmune disease
2. Pathogenesis of autoimmune disease10.1038/s41581-023-00720-1 ↗
3. Rheumatoid arthritis10.1016/S0140-6736(23)01525-8 ↗
4. Systemic lupus erythematosus: new diagnostic and therapeutic approaches10.1146/annurev-med-043021-032611 ↗
5. Sjögren's syndrome
6. Systemic sclerosis10.1016/S0140-6736(22)01692-0 ↗
7. ANCA-associated vasculitis10.1038/s41572-020-0204-y ↗
8. Type 1 diabetes10.1016/S0140-6736(23)00223-4 ↗
9. Pathobionts in inflammatory bowel disease: origins, underlying mechanisms, and implications for clinical care10.1053/j.gastro.2023.09.019 ↗
10. Inflammatory bowel disease presentation and diagnosis10.1016/j.suc.2019.08.001 ↗
11. Challenges and future trends in the treatment of psoriasis10.3390/ijms241713313 ↗
12. Antigen-specific immunotherapy for treatment of autoimmune liver diseases10.3389/fimmu.2020.01586 ↗
13. Diagnosis and treatment of multiple sclerosis: a review10.1001/jama.2020.26858 ↗
14. Control of immunity by glucocorticoids in health and disease10.1007/s00281-020-00827-8 ↗
15. Biologics in the treatment of skin and rheumatologic diseases10.1016/j.jaci.2020.02.017 ↗
16. Biologics for allergic and immunologic diseases10.1016/j.jaci.2022.08.009 ↗
17. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician10.1038/s41584-023-01062-9 ↗
18. Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis10.1136/ard-2023-223885 ↗
19. Adverse reactions to biologic agents: focus on autoimmune disease therapies10.1016/j.jaci.2005.03.028 ↗
20. Adverse events in patients with rheumatoid arthritis and psoriatic arthritis receiving long-term biological agents in a real-life setting10.3389/fphar.2019.00965 ↗
21. Paradoxical reactions to biologicals in chronic inflammatory systemic diseases
22. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis10.1136/annrheumdis-2019-216863 ↗
23. B cell depletion therapies in autoimmune disease: advances and mechanistic insights10.1038/s41573-020-00092-2 ↗
24. CAR T-cell therapy in autoimmune diseases10.1016/S0140-6736(23)01126-1 ↗
25. Regulation of immunity and autoimmunity by B cells10.1016/j.coi.2010.10.009 ↗
26. Regulatory T cells: the future of autoimmune disease treatment10.1080/1744666X.2019.1620602 ↗
27. Treg enhancing therapies to treat autoimmune diseases10.3390/ijms21197015 ↗
28. Emerging translational strategies and challenges for enhancing regulatory T cell therapy for graft-versus-host disease10.3389/fimmu.2022.926550 ↗
29. Advances in drug delivery and biomaterials: facts and vision10.3390/pharmaceutics11010048 ↗
30. Hydrogel encapsulation of mesenchymal stem cells and their derived exosomes for tissue engineering10.3390/ijms22020684 ↗
31. Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications10.1186/s40580-022-00310-0 ↗
32. Advances in biomaterials for drug delivery10.1002/adma.201705328 ↗
33. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery10.1080/17425247.2021.1828339 ↗
34. Engineering immune tolerance with biomaterials10.1002/adhm.201801419 ↗
35. Tissue-targeted drug delivery strategies to promote antigen-specific immune tolerance10.1002/adhm.202202238 ↗
36. Biomaterial strategies for selective immune tolerance: advances and gaps
37. Multiple natural polymers in drug and gene delivery systems
38. Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin10.1074/jbc.M117.794248 ↗
39. Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement10.1016/j.jconrel.2018.07.023 ↗
40. Clinical impact of serum proteins on drug delivery10.1016/j.jconrel.2011.11.028 ↗
41. Genetically Encoded elastin-like polypeptides for drug delivery10.1002/adhm.202100209 ↗
42. Intralacrimal sustained delivery of rapamycin shows therapeutic effects without systemic toxicity in a mouse model of autoimmune dacryoadenitis characteristic of Sjögren's syndrome10.1021/acs.biomac.0c01468 ↗
43. Hierarchical porous protein scaffold templated from high internal phase emulsion costabilized by gelatin and gelatin nanoparticles10.1021/acs.langmuir.7b04047 ↗
44. Current trends in gelatin-based drug delivery systems10.3390/pharmaceutics15051499 ↗
45. Protein and polypeptide mediated delivery to the eye10.1016/j.addr.2022.114441 ↗
46. Gelatin nanoparticles-HPMC hybrid system for effective ocular topical administration of antihypertensive agents10.3390/pharmaceutics12040306 ↗
47. Advancements in gelatin-based hydrogel systems for biomedical applications: a state-of-the-art review
48. Methotrexate-loaded gelatin and polyvinyl alcohol (Gel/PVA) hydrogel as a pH-sensitive matrix10.3390/polym13142300 ↗
49. Why Chitosan? From properties to perspective of mucosal drug delivery10.1016/j.ijbiomac.2016.05.054 ↗
50. Multiple roles of chitosan in mucosal drug delivery: an updated review10.3390/md20050335 ↗
51. Chitosan hydrogels for sustained drug delivery10.1016/j.jconrel.2020.06.012 ↗
52. Enhancing effects of chitosan and chitosan hydrochloride on intestinal absorption of berberine in rats10.3109/03639045.2011.592531 ↗
53. Lipid nanocarriers overlaid with chitosan for brain delivery of berberine via the nasal route10.3390/ph15030281 ↗
54. Anti-inflammatory activity of soluble chito-oligosaccharides (CHOS) on VitD3-induced human THP-1 monocytes10.1371/journal.pone.0246381 ↗
55. Application of chitosan/alginate nanoparticle in oral drug delivery systems: prospects and challenges10.1080/10717544.2022.2058646 ↗
56. Mucoadhesive nanoparticles enhance the therapeutic effect of dexamethasone on experimental ulcerative colitis by the local administration as an Enema10.2147/DDDT.S390274 ↗
57. Correction: Mucus-penetrating alginate-chitosan nanoparticles loaded with berberine hydrochloride for oral delivery to the inflammation site of ulcerative colitis10.1208/s12249-022-02376-9 ↗
58. The soluble and particulate form of alginates positively regulate immune response
59. Application of hyaluronic acid as carriers in drug delivery10.1080/10717544.2018.1450910 ↗
60. Self assembled hyaluronic acid nanoparticles as a potential carrier for targeting the inflamed intestinal mucosa10.1016/j.carbpol.2016.01.026 ↗
61. Combination therapy for ulcerative colitis: orally targeted nanoparticles prevent mucosal damage and relieve inflammation
62. Hyaluronic acid in ocular drug delivery10.1016/j.carbpol.2021.118006 ↗
63. Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis10.1038/s41563-019-0462-9 ↗
64. PLGA: a unique polymer for drug delivery10.4155/tde.14.91 ↗
65. Customizing poly(lactic-co-glycolic acid) particles for biomedical applications10.1016/j.actbio.2018.04.006 ↗
66. PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application10.1080/10717544.2021.1938756 ↗
67. PLGA particles in immunotherapy10.3390/pharmaceutics15020615 ↗
68. Exploiting PLGA-based biocompatible nanoparticles for next-generation tolerogenic vaccines against autoimmune disease10.3390/ijms20010204 ↗
69. Immunologically effective biomaterials10.1021/acsami.1c14781 ↗
70. Prophylactic and therapeutic effects of MOG-conjugated PLGA nanoparticles in C57Bl/6 mouse model of multiple sclerosis10.34172/apb.2021.058 ↗
71. Design of biodegradable nanoparticles to modulate phenotypes of antigen-presenting cells for antigen-specific treatment of autoimmune disease10.1016/j.biomaterials.2019.119432 ↗
72. Synthesis and biological application of polylactic acid10.3390/molecules25215023 ↗
73. Poly(lactic acid)-based microparticles for drug delivery applications: an overview of recent advances10.3390/pharmaceutics14020359 ↗
74. Porous core/dense shell PLA microspheres embedded with high drug loading of bupivacaine crystals for injectable prolonged release10.1208/s12249-020-01878-8 ↗
75. Novel electrospun nanofibrous matrices prepared from poly(lactic acid)/poly(butylene adipate) blends for controlled release formulations of an anti-rheumatoid agent10.1016/j.ejps.2016.03.021 ↗
76. Nanoparticles of poly(D,L-lactide)/methoxy poly(ethylene glycol)-poly(D,L-lactide) blends for controlled release of paclitaxel10.1002/jbm.a.30684 ↗
77. Studies of in situ-forming hydrogels by blending PLA-PEG-PLA copolymer with silk fibroin solution10.1002/jbm.a.33307 ↗
78. Poly(lactic acid)-based particulate systems are promising tools for immune modulation10.1016/j.actbio.2016.11.012 ↗
79. Enhanced humoral and cell-mediated immune responses generated by cationic polymer-coated PLA microspheres with adsorbed HBsAg10.1021/mp400597z ↗
80. In vitro and in vivo evaluation of immune response of poly(lactic acid) nanoparticles with different end groups
81. To PEGylate or not to PEGylate: immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives10.1016/j.addr.2021.114079 ↗
82. Poly(lactic acid) blends in biomedical applications10.1016/j.addr.2016.06.014 ↗
83. PEGylation enables subcutaneously administered nanoparticles to induce antigen-specific immune tolerance10.1016/j.jconrel.2021.01.013 ↗
84. Advanced metal and carbon nanostructures for medical, drug delivery and bio-imaging applications10.1039/D1NR07643D ↗
85. Gold nanoshell-linear tetrapyrrole conjugates for near infrared-activated dual photodynamic and photothermal therapies10.1021/acsomega.9b04150 ↗
86. Comparative effect of gold nanorods and nanocages for prostate tumor hyperthermia10.1016/j.jconrel.2015.10.036 ↗
87. Mechanisms of immune response to inorganic nanoparticles and their degradation products10.1016/j.addr.2021.114022 ↗
88. Gold nanoparticles downregulate interleukin-1β-induced pro-inflammatory responses10.1002/smll.201201528 ↗
89. Functional muscle recovery with nanoparticle-directed M2 macrophage polarization in mice10.1073/pnas.1806908115 ↗
90. Improved immunoregulation of ultra-low-dose silver nanoparticle-loaded TiO2 nanotubes via M2 macrophage polarization by regulating GLUT1 and autophagy10.2147/IJN.S242919 ↗
91. Adjuvant-loaded spiky gold nanoparticles for activation of innate immune cells10.1007/s12195-017-0505-8 ↗
92. Functionalized mesoporous silica nanoparticles in anticancer therapeutics10.1016/j.semcancer.2019.08.022 ↗
93. Engineered pH-responsive mesoporous carbon nanoparticles for drug delivery10.1021/acsami.0c01786 ↗
94. Graphene oxide finely tunes the bioactivity and drug delivery of mesoporous ZnO scaffolds10.1021/acsami.8b20728 ↗
95. Iron oxide nanoparticles for biomedical applications: A perspective on synthesis, drugs, antimicrobial activity, and toxicity
96. Autophagy upregulation promotes macrophages to escape mesoporous silica nanoparticle (MSN)-induced NF-κB-dependent inflammation10.1007/s00011-016-0919-0 ↗
97. Manganese-based immunomodulatory nanocomposite with catalase-like activity and microwave-enhanced ROS elimination ability for efficient rheumatoid arthritis therapy10.1002/smll.202304610 ↗
98. Engineered PD-1/TIGIT dual-activating cell-membrane nanoparticles with dexamethasone act synergistically to shape the effector T cell/Treg balance and alleviate systemic lupus erythematosus10.1016/j.biomaterials.2022.121517 ↗
99. Types and origins of bacterial membrane vesicles10.1038/s41579-018-0112-2 ↗
100. Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases10.1186/s40824-016-0068-0 ↗